Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    filgotinib Sjögren's syndrome
Previous Study | Return to List | Next Study

Safety and Efficacy Study of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03100942
Recruitment Status : Completed
First Posted : April 4, 2017
Last Update Posted : October 9, 2019
Sponsor:
Collaborator:
Galapagos NV
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib (previously GS-9876), and tirabrutinib (formerly GS-4059) in adults with active Sjogren's Syndrome (SjS).

Condition or disease Intervention/treatment Phase
Sjogren's Syndrome Drug: Filgotinib Drug: Lanraplenib Drug: Tirabrutinib Drug: Filgotinib placebo Drug: Lanraplenib placebo Drug: Tirabrutinib placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome
Actual Study Start Date : May 1, 2017
Actual Primary Completion Date : January 10, 2019
Actual Study Completion Date : October 2, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Filgotinib
Filgotinib + lanraplenib placebo + tirabrutinib placebo for 48 weeks
Drug: Filgotinib
200 mg tablet administered orally once daily
Other Name: GS-6034

Drug: Lanraplenib placebo
Tablet administered orally once daily

Drug: Tirabrutinib placebo
Tablet administered orally once daily

Experimental: Lanraplenib
Lanraplenib + filgotinib placebo + tirabrutinib placebo for 48 weeks
Drug: Lanraplenib
30 mg tablet administered orally once daily
Other Name: GS-9876

Drug: Filgotinib placebo
Tablet administered orally once daily

Drug: Tirabrutinib placebo
Tablet administered orally once daily

Experimental: Tirabrutinib
Tirabrutinib + filgotinib placebo + lanraplenib placebo for 48 weeks
Drug: Tirabrutinib
40 mg tablet administered orally once daily
Other Name: GS-4059

Drug: Filgotinib placebo
Tablet administered orally once daily

Drug: Lanraplenib placebo
Tablet administered orally once daily

Placebo Comparator: Placebo, then active treatment
Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants on placebo will be rerandomized to receive either filgotinib, lanraplenib, or tirabrutinib, in a blinded fashion and will continue treatment through Week 48
Drug: Filgotinib
200 mg tablet administered orally once daily
Other Name: GS-6034

Drug: Lanraplenib
30 mg tablet administered orally once daily
Other Name: GS-9876

Drug: Tirabrutinib
40 mg tablet administered orally once daily
Other Name: GS-4059

Drug: Filgotinib placebo
Tablet administered orally once daily

Drug: Lanraplenib placebo
Tablet administered orally once daily

Drug: Tirabrutinib placebo
Tablet administered orally once daily




Primary Outcome Measures :
  1. Proportion of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline [ Time Frame: Week 12 ]
    Response is defined in the protocol as composite improvement of biologic and patient reported outcomes.


Secondary Outcome Measures :
  1. Change from Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12 [ Time Frame: Baseline; Week 12 ]
    The ESSDAI is a physician-administered tool designed to measure disease activity.

  2. Change from Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12 [ Time Frame: Baseline; Week 12 ]
    The ESSPRI is a patient-reported questionnaire to assess subjective patient symptoms and includes 3 domains (dryness, pain, and fatigue).

  3. Change from Baseline in ESSDAI at Week 24 [ Time Frame: Baseline; Week 24 ]
    The ESSDAI is a physician-administered tool designed to measure disease activity.

  4. Change from Baseline in ESSPRI at Week 24 [ Time Frame: Baseline; Week 24 ]
    The ESSPRI is a patient-reported questionnaire to assess subjective patient symptoms and includes 3 domains (dryness, pain, and fatigue).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Diagnosed with SjS according to American European Consensus Group (AECG) classification
  • Active SjS as defined by an ESSDAI ≥ 5
  • Seropositivity for antibodies to SjS-associated antigens A and B (anti-SSA or anti-SSB)

Key Exclusion Criteria:

  • Concurrent treatment with any biologic disease modifying antirheumatic drug (bDMARD) (prior bDMARD treatment allowed with appropriate washout as per study protocol)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03100942


  Show 53 Study Locations
Sponsors and Collaborators
Gilead Sciences
Galapagos NV
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences

Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT03100942     History of Changes
Other Study ID Numbers: GS-US-445-4189
2016-003558-34 ( EudraCT Number )
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: October 9, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sjogren's Syndrome
Syndrome
Dry Eye Syndromes
Disease
Pathologic Processes
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases